5.0 PRE-STUDY EVALUATION REQUIREMENTS 
5.J p53 status of tumor tissue (altered p53 is an admission requirement; see Appendix F). 
5.2 The following must be performed within 2 weeks prior to study admission (except 
where noted): 
5.2.1 Complete history, physical examination, and toxicity evaluauon, including: 
Performance status (Appendix A). 
Height and weight, body surface area. 
Baseline toxicity evaluation. 
5.2.2 Laboratory screening (^eligibility criteria - see Section 3.8): 
CBC with differential*, platelet count*. 
Serum electrolytes (sodium, potassium, chloride, bicarbonate), BUN, 
creatinine*, glucose, uric acid, albumin, total protein, calcium, 
phosphorus, and magnesium. 
AST*, ALT*, total bilirubin*, alkaline phosphatase, LDH. 
PT*, PTT*. 
Hepatitis B serologies (HBsAg, HBsAb) 
Hepatitis C serologies (HCV Ab) 
Urinalysis. 
5.2.3 Electrocardiogram ( 1 2-lead) . 
5.2.4 Chest x-ray (PA and lateral views). 
5.2.5 SaC>2 determination, either by pulse oximetry or arterial blood gas analysis. 
5.2.6 Pulmonary function tests, including FEVi. 
5.2.7 Abdomen and pelvis CT or MRI scan. 
May be performed within 4 weeks prior to study admission. 
5.2.8 Tumor markers: 
Carcino-embryonic antigen (CEA) for patients with CRC. 
Alpha-fetoprotein (AFP) for patients with HCC. 
6.0 TREATMENT PLAN 
6.1 Route 
ACN53 will be administered in 50 to 500 cc of normal (0.9%) saline and infused over 10 
to 20 minutes by percutaneous hepatic arterial catheter. 
Recombinant DNA Research, Volume 20 
[679] 
